Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Nepal, Bangladesh scramble to secure COVID-19 shots as India curbs exports

CoronavirusMay 19, 2021 06:08AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: A woman holds on to the oxygen cylinders for a patient after refiling them at a factory, amidst the spread of coronavirus disease (COVID-19) surge as India's outbreak spreads across South Asia, in Kathmandu, Nepal May 9, 2021. REUTERS/Navesh C

By Gopal Sharma and Ruma Paul

KATHMANDU/DHAKA (Reuters) - Nepal and Bangladesh are making frantic diplomatic efforts to secure COVID-19 vaccines to prop up their faltering inoculation drives as their stocks run out and supply prospects have become clouded by a prolonged Indian curb on vaccine exports.

Reuters reported on Tuesday that India was unlikely to resume major exports of COVID-19 vaccines until October at the earliest as it diverts shots for domestic use, a longer-than-expected delay set to worsen a shortage of supplies coming through the COVAX global vaccine sharing scheme, designed to help low-income countries.

Bangladesh said it urgently needed 1.6 million doses of AstraZeneca (NASDAQ:AZN) Plc's COVID-19 vaccine to provide second doses and it had approached several countries for help, including the United States and Canada.

"Bangladesh foreign minister urged the Canadian High Commissioner to pursue with his government so that Bangladesh receives at least 2 million doses of AstraZeneca vaccine from Canada on an emergency basis," the foreign ministry said in a statement.

The ministry said its diplomats were also hoping to secure 4 million doses of the AstraZeneca vaccine from the United States, which plans to share up to 60 million doses of the vaccine.

Bangladesh has an agreement with the Serum Institute of India (SII), which manufactures the AstraZeneca shot, for 30 million doses, but has received only 7 million.

Bangladesh has also turned to China and Russia for supplies of China's Sinopharm and the Russian Sputnik V vaccines after India curbed vaccine exports in April.

Bangladesh has been relying on the AstraZeneca vaccine but only 2% of its 170 million people are fully vaccinated.


Nepal, which started its vaccination drive in January with 2.35 million doses of the AstraZeneca shot provided by India and COVAX, also said it has no stocks and more than 1.55 million people were waiting for their second dose.

"People above 65 and others in risk groups who received their first shots of the Indian vaccine are waiting for their second," Jhalak Gautam, head of the vaccine section of the Ministry of Health and Population, told Reuters.

"It's already overdue," he said, adding the SII had yet to deliver one million shots that Nepal bought.

The SII said on Tuesday it hoped to start supplying COVAX and delivering to other countries by the end of the year.

Nepal had asked Indian authorities for an early delivery of more shots, said Sewa Lamal, a spokesman for Nepal's Ministry of Foreign Affairs.

"Despite their own problems, we hope India can consider emergency requirements," she told Reuters.

India's foreign ministry did not comment on Nepal's request.

The head of the U.N. children's fund, which is helping supply COVID-19 vaccines through COVAX, on Monday asked G7 countries to donate supplies to COVAX as an emergency measure to address the severe shortfall caused by disruption to India's exports.

"There's a lot of back-door diplomacy happening to get extra doses from USA, EU and other 'rich' countries to make up for the backlog created by India," a source at UNICEF told Reuters.

The source said a lot of efforts were underway to resolve the supply disruptions and it could be too early to gauge the long-term impact of India's export curbs.

But the short-term impact of the reduced supply was already pronounced. UNICEF said this week that COVAX would deliver its 65 millionth vaccine dose this week, far behind its original target of 170 million.

Nepal, Bangladesh scramble to secure COVID-19 shots as India curbs exports

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email